Site icon pharmaceutical daily

Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Enrollment Initiated in Phase 2 Trial Cohort Evaluating SY-1425 and Azacitidine in Genomically Defined Patients with Relapsed or Refractory Acute Myeloid Leukemia

Multiple Clinical Data Readouts Expected for SY-1425 and SY-1365 in 2019 and 2020

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2019, and provided an update on recent accomplishments and upcoming events.

“This is an exciting time for Syros as we continue to advance our clinical-stage programs toward multiple data readouts this year and next that have the potential to validate our fundamental approach to drug development and catalyze change in the treatment landscape for cancers with high unmet needs,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “We plan to report updated clinical data for SY-1425 and SY-1365 in the fourth quarter, which we expect will provide additional insights into the safety and clinical activity of both drug candidates and further inform our development plans. We are particularly pleased to announce that we recently began enrolling relapsed or refractory AML patients in a new cohort in our Phase 2 trial of SY-1425 in combination with azacitidine. With this accomplishment, we now have three ongoing trial cohorts with potential for proof-of-concept data in 2020 that, if positive, bring us closer to our vision of providing much-needed therapies for patients.”

Upcoming Milestones:

SY-1425

SY-1365

SY-5609

Recent Pipeline Highlights:

Recent Corporate Highlights:

Second Quarter 2019 Financial Results:

Syros had cash, cash equivalents and marketable securities of $121.7 million as of June 30, 2019, as compared with $99.7 million in December 31, 2018. This increase in cash reflects aggregate net proceeds of approximately $65.0 million from Syros’ two concurrent underwritten public offerings, which closed in April 2019.

For the second quarter of 2019, Syros reported a net loss of $19.5 million, or $0.47 per share, compared to a net loss of $14.0 million, or $0.43 per share, for the same period in 2018.

Financial Guidance:

Based on its current plans, Syros believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its planned operating expenses and capital expenditure requirements to the end of the first quarter of 2021.

Conference Call and Webcast:

Syros will host a conference call today at 8:30 a.m. ET to discuss these second quarter 2019 financial results and provide a corporate update.

To access the live conference call, please dial (866) 595-4538 (domestic) or (636) 812-6496 (international), and refer to conference ID 7254685. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the call.

About Syros Pharmaceuticals:

Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial focused on patients with ovarian and breast cancers. Syros is also developing a deep preclinical and discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well as programs in oncology and sickle cell disease. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the Company’s ability to advance its clinical-stage programs, including the of the timing, quality and quantity of clinical data to be reported from the combination cohorts of the ongoing Phase 2 clinical trial of SY-1425 and the expansion phase of the ongoing Phase 1 clinical trial of SY-1365; the ability to complete enrollment in the cohort of the ongoing clinical Phase 2 clinical trial of SY-1425 in biomarker-positive newly diagnosed unfit AML patients; the ability to achieve clinical proof of concept and take advantage of fast-to-market opportunities for SY-1425 and SY-1365; the predictive value of the Company’s RARA and IRF8 biomarkers and develop a commercial companion diagnostic; the ability to complete IND-enabling preclinical studies and begin clinical development of SY-5609; the ability to report new preclinical data for SY-5609; the Company’s ability to fund its planned operations to the end of the first quarter of 2021; and the benefits of Syros’ gene control platform and product development pipeline. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including Syros’ ability to: advance the development of its programs, including SY-1425 and SY-1365, under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; successfully progress SY-5609 through IND-enabling preclinical and toxicology studies; replicate scientific and non-clinical data in clinical trials; successfully develop a companion diagnostic test to identify patients with the RARA and IRF8 biomarkers; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties, including its ability to perform under the collaboration agreement with Incyte; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption “Risk Factors” in Syros’ Annual Report on Form 10-K for the year ended December 31, 2018 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, each of which is on file with the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syros expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

Syros Pharmaceuticals, Inc.

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

 

 

June 30, 2019

 

December 31, 2018

Cash, cash equivalents and marketable securities

 

$

121,718

 

$

99,679

Working capital[1]

 

 

109,036

 

 

82,205

Total assets

 

 

151,827

 

 

106,766

Total stockholders’ equity

 

 

111,915

 

 

78,586

(1)

The Company defines working capital as current assets less current liabilities. See the Company’s condensed consolidated financial statements for further details regarding its current assets and current liabilities.

Syros Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

Three Months Ended

Six Months Ended

 

June 30,

June 30,

 

2019

 

2018

 

2019

 

2018

Revenue

$

462

$

375

$

916

$

745

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

15,475

 

11,082

 

28,037

 

22,198

General and administrative

 

5,195

 

3,841

 

10,061

 

7,916

Total operating expenses

 

20,670

 

14,923

 

38,098

 

30,114

Loss from operations

 

(20,208)

 

(14,548)

 

(37,182)

 

(29,369)

 

 

 

 

 

 

 

 

 

Other income, net

 

753

 

501

 

1,266

 

859

Net loss

$

(19,455)

$

(14,047)

$

(35,916)

$

(28,510)

 

 

 

 

 

 

 

 

 

Net loss per share – basic and diluted

$

(0.47)

$

(0.43)

$

(0.95)

$

(0.90)

 

 

 

 

 

 

 

 

 

Weighted-average number of common shares used in net loss per share – basic and diluted

 

41,673,275

 

32,892,712

 

37,741,646

 

31,621,303

 

Contacts

Media Contact:

Naomi Aoki

Syros Pharmaceuticals, Inc.

617-283-4298

naoki@syros.com


Investor Contact:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Exit mobile version